Agency for Medicinal Products and Medical Devices of the Republic of Slovenia
JAZMP is ambitious to further actively participate in assessment of marketing authorisation applications. In order to strengthen Slovenia’s position in the regulatory EU environment, one of the strategic objectives of […]
JAZMP AVAILABLE TO ACT AS REFERENCE MEMBER STATE (RMS) IN MRP AND DCP PROCEDURES Read More »
CT CURE, the European Union (EU) joint action seeking ways to expedite assessment and decisions on multinational clinical trial applications related to COVID-19 therapeutics, has entered its final year. The
Agency for medical products and medical devices of the Republic of Slovenia is committed to continuous improvement of its performance and has been actively participating in the Benchmarking of European
Benchmarking of European Medicines Agencies – BEMA Read More »
31 January 2024 was an important day for the entire European medicines regulatory network. The kick-off meeting of the Joint Action (JA) Supporting the increased capacity and competence building of
Kick-off meeting of the IncreaseNET Joint Action Read More »
The Agency of the Republic of Slovenia for Medicinal Products and Medical Devices (JAZMP) has taken over the role of coordinator of the Joint Action (JA) Project Supporting the increased
IncreaseNET project accepted for co-funding under the EU4Health programme Read More »
According to Article 58(12) of Regulation (EU) 2019/6, all Marketing Authorisation Holders must submit the annual Volume of Sales for each veterinary medicinal product to the Union Product Database (UPD).
The Agency for Medicines and Medical Devices of the Republic of Slovenia (JAZMP) and the Icelandic Medicines Agency – Lyfjastofnun (IMA) have signed a long-term agreement in the field of
